Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Naloxone for Pruritus in CTCL
NCT02811783Phase 3Terminated
- Sponsor
- Elorac, Inc.
- Start
- Jan 2017
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pruritus comparing Naloxone Hydrochloride Lotion, 0.5% with Placebo Lotion (2 arms). Primary endpoint: Numeric Rating Scale for Pruritus at 2 weeks. Started Jan 2017; status: terminated.
02
Drugs
naloxone
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT02811783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02811783.